- Home
- GOSS vs BRW Comparison
GOSS vs BRW Comparison
Compare GOSS & BRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- BRW
- Stock Information
- Founded
- GOSS 2015
- BRW 1987
- Country
- GOSS United States
- BRW United States
- Employees
- GOSS N/A
- BRW N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- BRW Trusts Except Educational Religious and Charitable
- Sector
- GOSS Health Care
- BRW Finance
- Exchange
- GOSS Nasdaq
- BRW Nasdaq
- Market Cap
- GOSS 347.8M
- BRW 355.1M
- IPO Year
- GOSS 2019
- BRW N/A
- Fundamental
- Price
- GOSS $2.47
- BRW $8.31
- Analyst Decision
- GOSS Strong Buy
- BRW
- Analyst Count
- GOSS 4
- BRW 0
- Target Price
- GOSS $8.50
- BRW N/A
- AVG Volume (30 Days)
- GOSS 3.1M
- BRW 222.1K
- Earning Date
- GOSS 08-05-2025
- BRW 01-01-0001
- Dividend Yield
- GOSS N/A
- BRW 15.59%
- EPS Growth
- GOSS N/A
- BRW N/A
- EPS
- GOSS N/A
- BRW N/A
- Revenue
- GOSS $40,237,000.00
- BRW N/A
- Revenue This Year
- GOSS N/A
- BRW N/A
- Revenue Next Year
- GOSS $30.65
- BRW N/A
- P/E Ratio
- GOSS N/A
- BRW N/A
- Revenue Growth
- GOSS N/A
- BRW N/A
- 52 Week Low
- GOSS $0.66
- BRW $7.15
- 52 Week High
- GOSS $2.65
- BRW $8.30
- Technical
- Relative Strength Index (RSI)
- GOSS 68.08
- BRW 50.04
- Support Level
- GOSS $2.38
- BRW $8.24
- Resistance Level
- GOSS $2.65
- BRW $8.46
- Average True Range (ATR)
- GOSS 0.15
- BRW 0.08
- MACD
- GOSS 0.03
- BRW -0.01
- Stochastic Oscillator
- GOSS 76.67
- BRW 31.82
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.